State by State Legislation Regarding Administering Medications in a School Setting
It is important that nurses research and inform themselves of their state's Nurse Practice Act, state regulations regarding the administration medications in the school, and school district policy for administering medication in school.
According to a 2004 review by the Center of Health and Health Care in Schools (CHHCS), called State Policies on Administration of Medication in the Schools, there are no states that prohibit the administration of a rectal medication by a licensed registered nurse if following a written order by a health care provider with prescriptive authority and with consent from the child's parent.
Some states, such as California, Connecticut, Delaware and Alabama, permit the school nurse to delegate the administration of medications to non-medical assistive personnel. Other states, such Idaho, Arkansas, and Colorado, do not have any regulations regarding the giving of medicine in school settings. These states defer to the school districts to create and implement policies.
Because of these differences among various states, it is important that you check your own state regulations. To do so, visit the Center for Health and Health Care in Schools today at http://www.healthinschools.org. The data on the Center's site was last updated/posted in July 2006 and is subject to change.
IMPORTANT SAFETY INFORMATION
DIASTAT® AcuDial™ (diazepam rectal gel) is a gel formulation of diazepam intended for rectal administration in the management of selected, refractory patients with epilepsy, on stable regimens of AEDs, who require intermittent use of diazepam to control bouts of increased seizure activity for patients 2 years and older.
In clinical trials with DIASTAT®, the most frequent side effect was somnolence (23%). Less frequent adverse events reported were dizziness, headache, pain, vasodilation, diarrhea, ataxia, euphoria, incoordination, asthma, rash, abdominal pain, nervousness and rhinitis (1%-5%). Please see full DIASTAT AcuDial Prescribing Information.
DIASTAT® AcuDial™ (diazepam rectal gel) is a gel formulation of diazepam intended for rectal administration in the management of selected, refractory patients with epilepsy, on stable regimens of AEDs, who require intermittent use of diazepam to control bouts of increased seizure activity for patients 2 years and older.
In clinical trials with DIASTAT®, the most frequent side effect was somnolence (23%). Less frequent adverse events reported were dizziness, headache, pain, vasodilation, diarrhea, ataxia, euphoria, incoordination, asthma, rash, abdominal pain, nervousness and rhinitis (1%-5%). Please see full DIASTAT AcuDial Prescribing Information.
© Valeant Pharmaceuticals North America 2007
Legal and Privacy Statement
DIASTAT® AcuDial™ is a registered trademark of Valeant Pharmaceuticals North America. D896-0607 Site Map